Scientific References

Schlesinger, S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin Biol Ther 1, 177-191 (2001)

Pushko, P. et al. Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239, 389-401 (1997)

Davis, N.L. et al. Alphavirus replicon particles as candidate HIV vaccines. Iubmb Life 53, 209-211 (2002)

Johnston, R.E. et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 23, 4969-4979 (2005)

Schultz-Cherry, S. et al. Influenza Virus (A/HK/156/97) Hemagglutinin Expressed by an Alphavirus Replicon System Protects Chickens against Lethal Infection with Hong Kong-Origin H5N1 Viruses. Virology 278, 55-59 (2000)

Weber, J.S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. The Lancet 403, 632-644 (2024)

Lundstrom, K. RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes 10, 189 (2019)

MacDonald, G.H. & Johnston, R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. Journal of virology 74, 914-922 (2000

Moran, T.P. et al. A novel viral system for generating antigen-specific T cells. J Immunol 175, 3431-3438 (2005)

Thompson, J.M. et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 103, 3722-3727 (2006)

Thompson, J.M., Whitmore, A.C., Staats, H.F. & Johnston, R.E. Alphavirus replicon particles acting as adjuvants promote CD8(+) T cell responses to co-delivered antigen. Vaccine 26, 4267-4275 (2008

Sumida, S.M. et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174, 7179-7185 (2005)

Kündig, T.M., Kalberer, C.P., Hengartner, H. & Zinkernagel, R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11, 1154-1158 (1993

Morse, M.A. et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. Journal of Clinical Investigation 120, 3234-3241 (2010)

Davis, N.L. et al. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 183, 20-31 (1991)

Pushko, P., Geisbert, J., Parker, M., Jahrling, P. & Smith, J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Journal of virology 75, 11677-11685 (2001)

Reap, E.A. et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 14, 748-755 (2007)

Rodrigues, C.M.C. & Plotkin, S.A. Impact of Vaccines; Health, Economic and Social Perspectives. Frontiers in Microbiology 11 (2020)

Elliott, M.B. et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132-7144 (2007)

Mok, H. et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. Journal of virology 81, 13710-13722 (2007)

Kowalski, J. et al. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 25, 2296-2305 (2007)

Colugnati, F.A.B., Staras, S.A.S., Dollard, S.C. & Cannon, M.J. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infectious Diseases 7, 71 (2007)

Bernstein, D.I. et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28, 484-493 (2009)

Wecker, M. et al. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 19, 1651-1660 (2012)

Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3, e525 (2006

Reap, E.A. et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25, 7441-7449 (2007)

Schleiss, M.R. et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. The Journal of infectious diseases 195, 789-798 (2007)

Davis, N.L. et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. Journal of virology 74, 371-378 (2000)

Hubby, B. et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25, 8180-8189 (2007)